Skip to main content
    Paid monthly and annual subscribers can read every Medi-Chi book online — including clinical references and the TCM Textbook · downloads sold separatelySee the libraryClinical Education Tool — This platform provides educational resources for TCM practitioners and students. It does not issue medical certificates, prescriptions, or clinical diagnoses.
    urology

    Renal papillary necrosis

    Also known as: RPN, Renal papillary infarction, Necrosis of the renal papillae

    Renal papillary necrosis is coagulative necrosis of the renal papillae and medullary pyramids, typically secondary to underlying systemic pathology or toxic exposures. Diagnosis necessitates clinical evaluation, kidney function testing, and diagnostic imaging. Management prioritises treating contributing conditions—such as diabetes mellitus or sickle cell disease—while addressing infection, obstruction, and potentially nephrotoxic exposures. TCM practitioners may provide adjunctive symptomatic support only following medical stabilisation. Cited evidence demonstrates no clinical proof that acupuncture or Chinese herbal medicine can resolve papillary necrosis or regenerate damaged renal tissue. Furthermore, investigations into cytokine pathways in diabetic microangiopathy do not establish therapeutic benefit for this specific pathology. Practitioners must remain vigilant regarding potential herbal nephrotoxicity and interactions.

    Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.

    All clinical details on this page are for practitioner premium subscribers only.
    Checking your practitioner access
    Verifying your Medi-Chi access…

    Lifestyle & Diet

    • •Adhere to a personalised fluid management plan, ensuring the avoidance of both dehydration and excessive fluid intake.
    • •Present all medicines, supplements, and herbal product labels to renal consultations; avoid non-steroidal anti-inflammatory drugs (NSAIDs) and other over-the-counter analgesics unless confirmed as safe for renal function by a medical officer.
    • •Maintain the agreed management plan for diabetes, blood pressure, or sickle cell disease, including prescribed medicines and monitoring.
    • •Monitor and record pain levels or urinary changes; engage in gentle physical activity and regular rest periods only once medical clearance has been obtained.

    Cautions & Contraindications

    See sources
    • •Defer elective acupuncture and herbal initiation during suspected infection, obstruction, acute kidney injury or unexplained visible haematuria until medically assessed. This is a clinical precaution informed by the disease review, not a tested acupuncture protocol.[]
    • •Avoid unverified or poorly labelled herbal products. Contamination, intrinsic toxicity and interactions can worsen renal injury; review every ingredient and monitor kidney function with the treating team.[]
    • •Do not substitute symptom improvement for renal monitoring or delay specialist care in diabetes or sickle cell disease. The supplied cytokine study does not test adjunctive treatment, and sickle cell disease can cause serious renal complications.[,,]

    When to reassess or seek care again

    See sources

    Medical follow-up takes priority and its timing depends on severity. If stable and cleared for adjunctive care, review after 1–2 weeks or 2–3 sessions using a 0–10 pain score, sleep disruption, urinary symptom frequency and daily function. Review clinician-ordered creatinine/eGFR, electrolytes and urinalysis when available; symptom relief is not evidence of tissue recovery. Stop and refer urgently for new red flags or worsening renal results. Discontinue an ineffective adjunctive trial rather than escalating treatment without reassessment.

    Explore more diseases

    Sources & Further Reading

    Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.

    1. Indian journal of nephrology · 2025
    2. Biomedicines · 2022
    3. Diabetes, metabolic syndrome and obesity : targets and therapy · 2024
    4. Cells · 2024

    Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.